Hemophilia is a rare, chronic disease caused by a deficiency of factor VIII (hemophilia A) or factor IX (hemophilia B) that impairs the normal process of coagulation. It is characterized by recurrent bleeding into the joints, muscles, and internal organs, resulting in chronic arthropathy and additional complications. A number of novel treatments have emerged with the potential of significantly reducing bleeds in patients with hemophilia, but patients frequently do not obtain optimal benefit from these therapies because clinicians lack a working knowledge of the latest data that can rationally inform clinical decision making. In addition, prophylaxis with recombinant or purified coagulation factor creates a high economic and personal burden for patients, and the development of inhibitors can further complicate treatment. Clinicians urgently require education on novel therapeutic approaches and on strategies to individualize treatment according to each patient s needs, preferences, and therapeutic response. To help close these major practice gaps, the proposed CME/NCPD-approved Video Viewpoint Strategy Session, featuring a discussion between two experts, will provide authoritative perspectives and evidence-based guidance on key clinical questions in the management of hemophilia A and B. What novel and emerging factor therapies provide significant advantages over existing factor therapies? What drives the need for alternatives to factor therapy? What do the data say about the efficacy and safety of novel and emerging gene therapies? Why is rebalancing hemostasis important in the treatment of hemophilia? What do the data say about the efficacy and safety of the hemostatic rebalancing agents that are in late-stage development? Will the advent of gene therapies, hemostatic rebalancing agents, and other novel forms of treatment spell the end of factor concentrates? What elements do you consider in choosing between treatment options for individual patients? If you have concerns about adherence for a particular patient, how does that impact your treatment selection and approach? What can health care providers do to improve adherence to treatment? How can pharmacokinetic-guided prophylaxis enhance treatment outcomes?
- Provider:i3 Health
- Activity Link: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia
- Start Date: 2024-06-21 05:00:00
- End Date: 2024-06-21 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours - MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Sanofi S.A. - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology